Director David Morton Fox filed a Form 4 with the SEC on November 12, 2026, reporting the exercise of Series A Warrants in MediWound Ltd. (NASDAQ:MDWD) on November 10, 2026.

Key Highlights

  • Warrant exercise: Fox exercised Series A Warrants to acquire 6,534 ordinary shares at an exercise price of $13.475 per share on November 10, 2026.
  • Cash payment: According to the filing, the aggregate exercise price was paid in cash, and no separate price was paid for the Series A Warrants upon exercise.
  • No shares sold: The filing states that Fox did not sell any of the ordinary shares acquired upon the exercise.
  • Post-transaction holdings: Following the transaction, Fox directly beneficially owned 28,817 ordinary shares.
  • Warrants extinguished: After the exercise, Fox held 0 Series A Warrants, down from 6,534, with the warrants expiring November 28, 2026.
  • RSU holding: Fox also holds 750 ordinary shares underlying RSUs granted March 4, 2026, vesting 100% on the one-year anniversary of the grant date.
  • Stock options: Fox holds multiple stock option grants totaling 46,541 underlying ordinary shares across seven separate grants, with exercise prices ranging from $11.885 to $37.52, with no transactions reported on those positions.

Fox Exercises Series A Warrants Before November 2026 Expiration

According to the Form 4 filed on November 12, 2026, David Morton Fox, a director of MediWound Ltd. (NASDAQ:MDWD), exercised Series A Warrants on November 10, 2026, acquiring 6,534 ordinary shares at an exercise price of $13.475 per share. The filing states the full aggregate exercise price was paid in cash, and no additional price was paid for the warrants themselves at the time of exercise. Fox did not dispose of any shares acquired through the exercise, the filing disclosed.

Following the reported transaction, Fox directly beneficially owned 28,817 ordinary shares. The Series A Warrants exercised had a listed expiration date of November 28, 2026, and Fox's beneficial ownership of those warrants was reduced to zero following the exercise. Separately, the filing notes Fox holds 750 ordinary shares underlying RSUs granted on March 4, 2026, which vest 100% on the one-year anniversary of the grant date.

The filing also includes, for informational purposes only, seven stock option grants with no transactions reported. Those options cover a total of 46,541 underlying ordinary shares, with exercise prices of $12.25, $37.52, $14.42, $11.885, $12.729, $18.54, and $17.60, and expiration dates ranging from June 29, 2030, to March 4, 2036. The option granted on March 4, 2026, covering 6,250 ordinary shares at $17.60, vests 100% on the one-year anniversary of the grant date, according to the filing.

What Was Disclosed

Director David Morton Fox reported the exercise of 6,534 Series A Warrants in MediWound Ltd. at $13.475 per share on November 10, 2026, paid in cash, with no shares sold. His resulting direct beneficial ownership of ordinary shares was 28,817.